VisEn Medical, a developer of agents and systems in the field of molecular imaging, has a new partner. Siemens has taken an equity stake in the company in an effort to promote the development of MI technology and expand the markets for in vivo imaging of
VisEn Medical, a developer of agents and systems in the field of molecular imaging, has a new partner. Siemens has taken an equity stake in the company in an effort to promote the development of MI technology and expand the markets for in vivo imaging of molecular events. VisEn, which was founded in June 2000 on technologies developed at Massachusetts General Hospital and Harvard Medical School, is focusing on technology for imaging cancer, atherosclerosis, and rheumatoid arthritis.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.